Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more

Recent & Breaking News (NDAQ:RXRX)

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

GlobeNewswire 4 days ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

GlobeNewswire 11 days ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

GlobeNewswire 12 days ago

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 6, 2024

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

GlobeNewswire October 30, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

GlobeNewswire October 22, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

PR Newswire October 15, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

PR Newswire October 15, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI

Accesswire October 11, 2024

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire October 2, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders

PR Newswire September 24, 2024

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

GlobeNewswire September 3, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE on Behalf of Shareholders

PR Newswire August 9, 2024

Lifshitz Law PLLC Announces Investigations of GVP, RXRX, OBDE, and TWKS

Accesswire August 8, 2024

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Recursion Pharmaceuticals, Inc. Merger

Newsfile August 8, 2024

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders

Business Wire August 8, 2024

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

GlobeNewswire August 8, 2024

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

GlobeNewswire August 8, 2024